Federal Circuit Grants Rehearing, Declares Novartis Patent Invalid

Mealey's (June 22, 2022, 7:34 AM EDT) -- WASHINGTON, D.C. — In a June 21 holding, a divided Federal Circuit U.S. Court of Appeals said a Delaware federal judge’s finding that a “no-loading-dose” limitation in a patented multiple treatment has adequate written description was clearly erroneous....